LAUSR

vancomycin, all of which can increase our understanding of drugs in the eye. Grzybowski and Bardeci mentioned the cases of hypersensitivity, including the first case of anaphylaxis caused by topical moxifloxacin drops reported in the same issue of the journal as our paper. It is not surprising to find rare allergic cases, even severe ones, given the millions of topical moxifloxacin 0.5% (Vigamox) drops administered globally to date. Moxifloxacin has never been reported to cause severe ophthalmic sequelae such as hemorrhagic occlusive retinal vasculitis or toxic anterior segment syndrome resulting from dilution errors. However, a recent report of a significant reduction in the rate of infective postoperative endophthalmitis with intracameral moxifloxacin in a series of over 600 000 cases has added another layer of evidence to the mountain of data supporting intracameral moxifloxacin use. There are no perfect drugs, and when one superior to moxifloxacin becomes available, we will certainly consider transitioning.dSteve A. Arshinoff, MD, FRCSC, Milad Modabber, MD, MSc